Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGL | P06737 | 5/20 | 0.66 |
| ▸ | PYGM | P11217 | 5/20 | 0.66 |
| ▸ | RIPK1 | Q13546 | 14/20 | 0.60 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.52 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4232147 | 1.00 | PYGL (0.66) | PYGLPYGMRIPK1DDB1CRBN | |
| SCHEMBL4216634 | 1.00 | PYGL (0.66) | PYGLPYGMRIPK1DDB1CRBN | |
| SCHEMBL22469203 | 0.92 | PYGL (0.57) | PYGLPYGMRIPK1DDB1CRBN | |
| Benzylacetone SCHEMBL1980507 | 0.86 | RIPK1 (0.56) | PYGLPYGMRIPK1 | |
| SCHEMBL25329367 | 0.85 | PYGL (0.64) | PYGLPYGMRIPK1 | |
| SCHEMBL29900499 | 0.85 | PYGL (0.64) | PYGLPYGMRIPK1 | |
| SCHEMBL15541576 | 0.85 | PYGL (0.64) | PYGLPYGMRIPK1 | |
| SCHEMBL19207650 | 0.84 | PYGL (0.49) | PYGLPYGMRIPK1 | |
| SCHEMBL3989268 | 0.84 | PYGL (0.53) | PYGLPYGMRIPK1DDB1CRBN | |
| SCHEMBL3914513 | 0.84 | PYGL (0.53) | PYGLPYGMRIPK1DDB1CRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2509981-B1 | INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE | LILLY CO ELI (US) | 2014-08-06 | — | — | EP | disclosed |
| US-8299061-B2 | Inhibitors of diacylglycerol acyltransferase | ELI LILLY AND COMPANY (US) | 2012-10-30 | — | — | US | disclosed |
| EP-2509981-A1 | INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE | Eli Lilly and Company (US) | 2012-10-17 | — | — | EP | disclosed |
| US-20110144091-A1 | Inhibitors of Diacylglycerol Acyltransferase | ELI LILLY AND COMPANY (US) | 2011-06-16 | — | — | US | disclosed |
| WO-2011071840-A1 | INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE | ELI LILLY AND COMPANY (US) | 2011-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144091-A1 | Inhibitors of Diacylglycerol Acyltransferase | DGAT1, DGAT2, LCAT | PYGL 1736/4885PYGM 2741/4885RIPK1 3703/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.